On Oct 17, Mattel, Inc. (NASDAQ:MAT), posted profit that trailed analysts’ estimates as sales of Barbie dolls dropped for a fourth straight quarter. Third-quarter net income shrank 22 percent to $331.8 million, or 97 cents a share, from $422.8 million, or $1.21, the El Segundo, California-based company said today in a statement. Analysts had predicted $1.02 a share, on average, based on 12 estimates compiled by Bloomberg Mattel, Inc. (NASDAQ:MAT) belongs to Consumer Goods sector. Its net profit margin is 11.60% and weekly performance is -2.43%. On last trading day company shares ended up $29.47. Mattel, Inc. (NASDAQ:MAT) distance from 50-day simple moving average (SMA50) is -11.16%.

ISI Group assumed coverage on shares of Weatherford International Plc (NYSE:WFT) in a research note issued on Wednesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.Weatherford International plc (NYSE:WFT) shares increased 1.16% in last trading session and ended the day at $16.58. WFT Gross Margin is 20.40% and its return on assets is -2.00%. Weatherford International plc (NYSE:WFT) quarterly performance is -28.26%.

Synta Pharmaceuticals Corp. (NASDAQ:SNTA) Director Bruce Kovner acquired 300,000 shares of Synta Pharmaceuticals Corp. stock in a transaction dated Tuesday, September 30th. The stock was purchased at an average price of $3.08 per share, for a total transaction of $924,000.00. Following the transaction, the director now directly owns 3,060,860 shares of the company’s stock, valued at approximately $9,427,449.On 20 October, Synta Pharmaceuticals Corp. (NASDAQ:SNTA) shares increased 3.30% and was closed at $3.13. SNTA EPS growth in last 5 year was 14.30%. Synta Pharmaceuticals Corp. (NASDAQ:SNTA) year to date (YTD) performance is -40.27%.

Nexcelle is delivering on its integrated propulsion systems (IPS) vision for business aviation, having provided the nacelle for flight tests of General Electric Company (NYSE:GE) Aviation’s Passport turbofan engine; completing initial ground tests to support this new 16,000-lb.-thrust category powerplant’s certification; and ramping up the manufacture of nacelle components at facilities in both France and the U.S. On 20 October, General Electric Company (NYSE:GE) shares advanced 0.85% and was closed at $25.03. GE EPS growth in last 5 year was -3.80%. General Electric Company (NYSE:GE) year to date (YTD) performance is -8.42%.

On Oct. 6, Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) announced results from the pivotal Phase 3 VALOR trial, a randomized, double-blind, placebo-controlled trial of vosaroxin and cytarabine in patients with first relapsed or refractory acute myeloid leukemia (AML). At more than 100 leading international sites, the trial enrolled 711 patients, who were stratified for age, geography and disease status. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) shares increased 4.17% in last trading session and ended the day at $1.50. SNSS return on assets is -75.40%. Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) quarterly performance is -74.36%.